Drug intelligence / Profile preview

n-acetylcarnosine + vaccinium myrtillus + chondroitin sulfate

Development stage
Unknown
Lead developer
Innovative Vision Products
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

This is a **combination ophthalmic formulation** containing the following active ingredients: **n-acetylcarnosine**, **vaccinium myrtillus extract**, and **chondroitin sulfate**. - **N-acetylcarnosine** acts as a prodrug of carnosine, a water-soluble antioxidant, and is believed to exert protective effects in the eye by scavenging reactive oxygen species, preventing lipid peroxidation, and protecting lens proteins from oxidation, thus potentially delaying or improving age-related cataract development[3][5]. - **Vaccinium myrtillus extract** (bilberry extract) is rich in anthocyanins, which function as antioxidants and may help support retinal microcirculation and reduce oxidative stress. - **Chondroitin sulfate** is a glycosaminoglycan with lubricating and anti-inflammatory properties used to enhance ocular surface moisture, stabilize the tear film, and protect the corneal epithelium. This combination is marketed for ophthalmic use, primarily as **eye drops** for the prevention and management of cataracts, improvement of visual function, and protection against oxidative stress and inflammation in the eye[1][3][5].

Brand names
lacristal
02

Targets

CRYAA (Alpha-crystallin A chain)

Beyond the preview

Go deeper on n-acetylcarnosine + vaccinium myrtillus + chondroitin sulfate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-acetylcarnosine + vaccinium myrtillus + chondroitin sulfate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call